evipedia.aidev
← Back

Saffron Extract for Health & Longevity

Evidence Review created on 08/14/2026 using AI4L / Grok 4

Also known as: Crocus sativus Extract, Saffron Stigma Extract, Saffron

Motivation

Saffron extract is a concentrated preparation of the dried red threads of the Crocus sativus flower — the same spice long used in cooking. Standardized capsules, usually 15 to 30 milligrams a day, are taken for mood, sleep, and later-life brain function. The main plant chemicals are crocin, crocetin, and safranal.

The spice has a multi-thousand-year record in Persian and other traditional systems, mainly for low mood. Modern extract research began in the mid-2000s with Iranian clinical trials and later branded-product studies. Product quality is uneven: some capsules contain little authentic material. Many newer trials use branded extracts paid for by their makers, while several foundational studies come from a small group of academic centers. Several of those trials report mood changes in the same range as common antidepressant drugs.

This review examines the human evidence on saffron extract for health and longevity: how it works, what benefits and harms the trials show, who appears more or less likely to respond, how products differ, and what a typical protocol looks like.

Benefits - Risks - Protocol - Conclusion

High-level overviews of saffron extract that map the clinical landscape without substituting for trial-level evidence.

No dedicated FoundMyFitness, Peter Attia, or Lifespan.io pieces discussed saffron extract in substantial depth; those platforms either returned no on-site hits or only passing mentions of crocin inside broader polyphenol notes.

Grokipedia

  • Saffron

    Encyclopedia-style page on the spice, botany, and traditional use. Useful background; it is not a trial-level review of extract dosing.

Examine

  • Saffron

    Independent monograph grading outcomes across 65 trials and 11 meta-analyses, with a usual dose of 15 mg twice daily and a structured safety section.

ConsumerLab

  • Saffron Supplements Review

    Independent product tests of safranal, picrocrocin, and crocin content, a clinical-evidence summary, and Top Picks. Several retail extracts have failed authenticity checks.

Systematic Reviews

Pooled human evidence on saffron extract for mood, cognition, sleep, and safety.

Mechanism of Action

Saffron extract is prepared from the dried stigmas of Crocus sativus. The dominant actives are crocin, a water-soluble color compound; crocetin, the form the body actually absorbs; safranal, a volatile aroma compound; and picrocrocin, a bitter taste compound.

After swallowing, gut enzymes hydrolyze crocin to crocetin. In healthy adults, crocetin reaches peak plasma levels in about 4.0–4.8 hours and leaves plasma with a half-life of about 6.1–7.5 hours (Umigai et al., 2011). Intact crocin itself has very low oral bioavailability. Safranal is more fat-soluble and is processed in part by cytochrome P450 enzymes, the liver proteins that break down many drugs. Crocetin distributes into plasma and, in experimental work, liver, kidney, and retina, with limited brain entry.

Mood effects are usually attributed to a mild rise in synaptic serotonin (the chemical that supports mood stability), together with antioxidant and anti-inflammatory actions and possible dampening of the hypothalamic–pituitary–adrenal stress-hormone axis. In laboratory models, crocin and crocetin slow amyloid-β clumping and support retinal photoreceptors. A competing view holds that any mood change is secondary to better sleep, lower perceived stress, or expectancy, especially in small manufacturer-funded trials. Unlike a pharmaceutical antidepressant, the extract is not a single-receptor agent. The observed half-life is compatible with once- or twice-daily oral dosing.

Historical Context & Evolution

Saffron has been used as a spice, dye, and medicine for more than two millennia in Persian, Greek, Ayurvedic, and East Asian systems, mainly for low mood, menstrual discomfort, digestion, and eye complaints. Therapeutic interest in measured extracts grew after Iranian randomized trials in the mid-2000s reported that about 30 mg/day of stigma extract improved mild-to-moderate depression to a similar degree as fluoxetine or imipramine (Noorbala et al., 2005). Those actual score changes — not later commentary on sample size — opened Western supplement use.

Branded extracts (affron, Safr’Inside, Satiereal), often funded by their manufacturers, then expanded trials into sleep, subclinical mood, and snacking. An Italian group studied 20 mg/day for early age-related macular degeneration using retinal electrical responses rather than only questionnaires (Falsini et al., 2010). Opinion moved from “culinary spice” to candidate mood and sleep nutraceutical as meta-analyses accumulated. The same literature still leaves open how far those results generalize beyond the original Iranian clinical samples or industry-sponsored branded products. Therapeutic doses have not shown the gram-level toxicity described in older materia medica; that historical harm signal remains tied to much larger amounts of the spice.

Expected Benefits

High 🟩 🟩 🟩

Depressive symptom reduction ⚠️ Conflicted

Standardized stigma extract, usually 30 mg/day, reduces mild-to-moderate depressive symptoms versus placebo and matches fluoxetine-class antidepressants in several randomized-trial meta-analyses. Proposed routes include serotonin signaling and better sleep. A 2025 synthesis found no difference versus those drugs and fewer adverse events; an earlier pool reported a large placebo-controlled effect, while a 34-trial GRADE pool (Mahmoudi et al., 2026) lowered Beck scores but not clinician-rated Hamilton scores. Branded-extract trials are often manufacturer-funded. A 2025 subclinical-mood trial was null (Amadieu et al., 2025), so the clinical-depression signal is the stronger one.

Magnitude: Hedges g 0.89 (a standardized effect size; about 0.8 is large) versus placebo in mild-to-moderate depression; no difference versus SSRIs (standardized mean difference 0.10, a near-zero head-to-head gap) (Tóth et al., 2019; Shafiee et al., 2025).

Medium 🟩 🟩

Anxiety symptom reduction ⚠️ Conflicted

Randomized trials and a 2025 head-to-head meta-analysis find anxiety-score change similar to SSRIs. A separate pool reported a several-point drop on the Beck Anxiety Inventory but no change on the Hamilton anxiety scale, so the instrument used matters. The usual studied dose is 30 mg/day. The anxiety evidence is thinner and more mixed than the depression evidence.

Magnitude: Beck Anxiety Inventory weighted mean difference −5.29 points (average change across trials); SSRI-comparison standardized mean difference 0.04 (nonsignificant) (Ghaderi et al., 2020; Shafiee et al., 2025).

Sleep quality and duration

Extracts used for mood also improve subjective sleep quality, sleep duration, and insomnia-severity scores versus placebo in a systematic review of eight trials. Typical regimens are 14 mg twice daily or about 15.5 mg once daily for 4–6 weeks. Objective actigraphy (wrist-worn sleep tracking) changes are smaller than questionnaire changes. Manufacturer funding is common in the branded-extract sleep studies.

Magnitude: Sleep-quality standardized mean difference 0.89 and duration 0.57 versus placebo; Pittsburgh Sleep Quality Index (a 0–21 sleep-quality questionnaire) about −2.2 points in pooled trials (Munirah et al., 2022; Ghaderi et al., 2020).

Low 🟩

Cognitive scores in mild cognitive impairment and Alzheimer disease

Small randomized trials report better Alzheimer Disease Assessment Scale–cognitive subscale and clinical dementia scores versus placebo at 16 weeks, and no difference versus donepezil or memantine. A five-trial systematic review flagged high risk of bias and narrow samples.

Magnitude: Cognitive and global scores improved versus placebo at 16 weeks; 12-month course comparable to memantine 20 mg/day. The literature reports no pooled point-change figure (Akhondzadeh et al., 2010; Avgerinos et al., 2020).

Premenstrual symptom relief

One double-blind trial in women with regular cycles found 30 mg/day for two menstrual cycles lowered daily premenstrual symptom totals and depression scores versus placebo. The likely route is the same mood mechanism as in depression trials. Replication outside a single center is limited.

Magnitude: 15 of 25 women met Hamilton-depression response versus 1 of 25 on placebo over two cycles at 30 mg/day (Agha-Hosseini et al., 2008).

Sexual function

Two 4-week fluoxetine add-on trials at 30 mg/day improved selected sexual-function domains versus placebo. A 2018 trial meta-analysis also reported erectile-function score gains outside that add-on setting. Desire often did not change in the add-on trials.

Magnitude: In men on fluoxetine, 60% versus 7% reached normal erectile-function scores after 4 weeks at 30 mg/day; a three-trial pool reported a 5.36-point erectile-function gain (Modabbernia et al., 2012; Kashani et al., 2013; Maleki-Saghooni et al., 2018).

Early macular flicker sensitivity

A crossover trial of 20 mg/day for 3 months increased macular flicker-response amplitude on focal electroretinography (a retina electrical test) versus placebo in early age-related macular degeneration. A follow-up series suggested the electrical gain can persist with continued use. Visual-acuity gains are modest and samples are small.

Magnitude: Macular flicker-response amplitude rose 0.25 log μV after 3 months at 20 mg/day, versus essentially no placebo change (Falsini et al., 2010).

Appetite, snacking, and modest weight change

A branded extract (176.5 mg/day for 8 weeks) reduced self-reported snacking and body weight versus placebo in mildly overweight women, attributed to mood rather than a stimulant-like appetite block. A cardiovascular-risk meta-analysis found about 1 kg less weight and a small waist change, without consistent lipid improvement.

Magnitude: Pooled trials about −1.29 kg body weight and −1.68 cm waist; one branded extract cut snacking over 8 weeks (Pourmasoumi et al., 2019; Gout et al., 2010).

Glycemic markers in type 2 diabetes

A 2024 meta-analysis of randomized trials found saffron extract and isolated crocin lowered fasting glucose and glycated hemoglobin (the three-month blood-sugar average) in type 2 diabetes. Effect sizes vary by preparation, and many trials are short. This is an add-on metabolic signal, not a substitute for glucose-lowering drugs.

Magnitude: Extract associated with fasting glucose about −27 mg/dL and glycated hemoglobin −0.35% (Amatto et al., 2024).

Attention-deficit hyperactivity symptoms

A systematic review of four small randomized trials (118 people) reported attention-deficit hyperactivity symptom improvement as monotherapy or with methylphenidate. Samples are brief and geographically narrow, so the signal remains tentative (Seyedi-Sahebari et al., 2024).

Magnitude: Parent- and teacher-rated attention-deficit hyperactivity scores improved in four small trials; the literature reports no pooled point-change figure (Seyedi-Sahebari et al., 2024).

Speculative 🟨

Healthy-aging neuroprotection without cognitive impairment

Laboratory work on amyloid, oxidation, and retinal genes, plus one small trial in cognitively normal adults, is the main basis. Controlled evidence that extract extends healthspan or preserves cognition in unimpaired adults is not established.

Systemic inflammatory markers

A meta-analysis of C-reactive protein, tumor necrosis factor-α, and interleukin-6 found no overall change (Asbaghi et al., 2021). Subgroup dips in C-reactive protein at ≤30 mg/day do not establish an anti-inflammatory benefit.

Benefit-Modifying Factors

  • Baseline mood severity: Clinical mild-to-moderate depression shows a clearer, larger signal than subclinical low mood. A 2025 healthy-adult trial with mixed low-grade symptoms did not beat placebo on its composite mood score (Amadieu et al., 2025).

  • Extract identity and dose: Standardized stigma extracts at 28–30 mg/day dominate positive mood and sleep trials. Isolated crocin, petal extract, and culinary spice are not interchangeable with those capsules.

  • Sex: PMS and satiety trials enrolled women; fluoxetine-related sexual-function trials were sex-specific. Depression and anxiety pools are mixed and do not show a consistent sex-by-treatment interaction.

  • Age: Alzheimer and macular-degeneration trials enrolled older adults and still reported cognitive or retinal signals. Sleep and mood trials include midlife adults; pediatric use is outside this review.

  • Retinal genotype: In early macular degeneration, complement factor H and ARMS2 risk variants (common macular-degeneration susceptibility genes) did not block the flicker-response gain (Marangoni et al., 2013).

  • Metabolic baseline: Fasting-glucose and glycated-hemoglobin shifts appear mainly in type 2 diabetes, not in metabolically healthy users.

  • Trial funding: Manufacturer-funded branded-extract studies often report sleep and subclinical-mood gains; independent Iranian clinical-depression trials remain the backbone of the high-evidence mood claim.

Potential Risks & Side Effects

High 🟥 🟥 🟥

High-dose toxicity, including uterine stimulation

Gram quantities of the spice — not 15–30 mg extract — have long been described as poisonous and as a uterine stimulant. Case series and toxicology reviews list vomiting, dizziness, bloody diarrhea, mucosal bleeding, yellow discoloration, miscarriage risk, and, at 12–20 g, death. Therapeutic extract doses in clinical trials have not reproduced that picture (Bostan et al., 2017).

Magnitude: Poisoning described at ≥5 g of spice; 12–20 g historically linked to death. Typical extract regimens are 15–30 mg/day.

Medium 🟥 🟥

Common gastrointestinal and neurologic adverse events

Nausea, dry mouth, appetite change, headache, and drowsiness are the events most often listed in trials and safety reviews. A 12-trial synthesis found no excess versus placebo, and a 2025 SSRI-comparison found fewer events on saffron (risk difference −0.06, the absolute gap in event rates). Events are usually mild and reverse when the extract is stopped (Dai et al., 2020; Shafiee et al., 2025).

Magnitude: Adverse-event risk difference −0.06 (the absolute gap in event rates) versus SSRIs; incidence not higher than placebo in a 12-trial safety meta-analysis.

Low 🟥

Blood-pressure and blood-count shifts at high extract doses

In healthy volunteers, 400 mg/day of saffron tablets for 7 days lowered standing systolic pressure and slightly lowered red-cell and platelet counts. That dose is more than tenfold the usual mood protocol (Modaghegh et al., 2008).

Magnitude: Standing systolic pressure and selected blood counts moved after 400 mg/day for 1 week; 200 mg/day was closer to placebo. The literature reports no millimeter-of-mercury or cell-count figure.

Speculative 🟨

Bleeding tendency

Laboratory work shows slower platelet clumping. A 1-week trial of 200 and 400 mg tablets found no change in clotting tests (Ayatollahi et al., 2014), so a clinical bleeding effect at supplement doses is unproven.

Serotonin excess with other serotonergic agents

Serotonergic extract plus 5-hydroxytryptophan (5-HTP) or St. John’s wort is a theoretical concern. Fluoxetine add-on trials at 30 mg/day did not report serotonin syndrome (dangerous excess serotonin signaling) (Kashani et al., 2013).

Mood elevation in bipolar spectrum illness

Isolated reports and mechanistic caution exist for a mood lift that could unmask mania. Controlled bipolar data are essentially absent, so this remains a theoretical risk rather than a measured rate.

Risk-Modifying Factors

  • Dose: Toxicity and blood-count shifts appear at gram spice doses or ≥200–400 mg extract, not at 15–30 mg/day used in mood trials (Modaghegh et al., 2008).

  • Pregnancy status: Therapeutic and high culinary doses are the main setting for uterine-stimulation concern. Food-spice amounts in cooking are the historical exception, not a studied safe ceiling.

  • Baseline blood pressure and glucose: People already on antihypertensives or glucose-lowering drugs have more room for additive lowering if dose creeps upward.

  • Sex: PMS and pregnancy-related risks apply to people who menstruate or can become pregnant. Sexual-function adverse-event rates in depression trials have not shown a consistent sex split.

  • Age: Older adults in Alzheimer and macular trials tolerated 20–30 mg/day. Frailty, taking many medicines, and fall risk make drowsiness more relevant after midlife.

  • Bipolar predisposition: Any serotonergic botanicals can, in principle, lift mood too far; this is a mechanistic caution, not a quantified saffron-specific rate.

  • Product authenticity: Adulterated capsules can deliver unexpected plants or dyes, changing both risk and benefit independently of crocin pharmacology.

Key Interactions & Contraindications

  • SSRIs (fluoxetine, sertraline, escitalopram) — caution: Theoretical extra serotonergic tone. Fluoxetine add-on trials at 30 mg/day did not raise adverse-event rates. Combined-use protocols typically watch mood and autonomic symptoms (Kashani et al., 2013).

  • Other serotonergic supplements (5-hydroxytryptophan / 5-HTP, St. John’s wort, S-adenosylmethionine / SAMe) — caution: Additive serotonergic effect is plausible. Combined-use protocols typically hold the extract at 30 mg/day or lower and watch for agitation or tremor.

  • Additive hypotensive, glucose-lowering, or sedating supplements (magnesium, berberine, melatonin) — caution: Combined-use protocols typically watch for extra blood-pressure or glucose dips and next-day drowsiness.

  • Antihypertensives (amlodipine, lisinopril, losartan) — monitor: Higher extract doses lowered standing systolic pressure in volunteers. Treated-hypertension protocols typically recheck blood pressure after the first 1–2 weeks (Modaghegh et al., 2008).

  • Glucose-lowering drugs (metformin, insulin, semaglutide) — monitor: Extract and crocin can lower fasting glucose. Add-on protocols with glucose-lowering drugs typically track home glucose (Amatto et al., 2024).

  • Anticoagulants and antiplatelets (warfarin, apixaban, aspirin) — monitor: In vitro platelet inhibition exists; a human coagulation trial at 200–400 mg was null. Combined-use protocols typically watch for bruising (Ayatollahi et al., 2014).

  • Sedating drugs (diphenhydramine, zolpidem, lorazepam) — caution: Shared drowsiness. Evening extract timing is common for sleep; combining with hypnotics can deepen next-day residual drowsiness.

  • CYP1A2 (a liver enzyme that breaks down caffeine and some drugs) substrates (caffeine, theophylline, clozapine) — caution: Safranal can interact with this enzyme in experimental systems. Clinical magnitude is unclear; unexpected caffeine sensitivity is the practical flag.

Populations who should avoid Saffron Extract:

  • Pregnancy at supplemental or medicinal doses (uterine stimulant; miscarriage concern above food-spice amounts)
  • Lactation (human safety not established)
  • Active plans for conception while using therapeutic capsules
  • Known saffron or Crocus allergy

Risk Mitigation Strategies

  • Stay at studied extract doses: 15–30 mg/day of standardized stigma extract keeps intake two orders of magnitude below gram-level toxic spice amounts.

  • Split or evening timing: 15 mg twice daily, or a single evening dose for sleep, limits peak-related nausea and daytime drowsiness.

  • Authenticate the product: Third-party tests for crocin, picrocrocin, and safranal reduce the chance of empty or adulterated capsules that fail to match the trials.

  • Blood-pressure and glucose checks: Home readings in the first month catch additive lowering in people already treated for hypertension or diabetes.

  • Hold before major surgery: Elective-surgery protocols typically hold the extract 1–2 weeks beforehand as a precaution around the unresolved platelet question.

  • Serotonergic botanical stacking: Protocols typically omit St. John’s wort or high-dose 5-HTP alongside the extract to reduce theoretical serotonin-excess risk.

  • Pregnancy screen: Therapeutic-course protocols typically confirm non-pregnancy first; this is the main absolute-avoidance rule.

Therapeutic Protocol

  • Usual studied regimen: 15 mg standardized stigma extract twice daily, or 28–30 mg once daily, for at least 4–8 weeks. This is the dose used by Iranian psychiatry groups and in most affron trials (Lopresti / Clinical Research Australia).

  • Sleep-focused variant: 14 mg twice daily or 15.5 mg in the evening for 4–6 weeks, as in the affron and Saffr’Inside sleep studies.

  • Retinal variant: 20 mg once daily, the Falsini/Bisti early macular-degeneration protocol, often continued for months if flicker-response or acuity is being tracked.

  • Time of day: Morning-and-evening split matches the 6–7.5-hour crocetin half-life. A single evening dose is common when sleep is the target.

  • Single versus split dose: Split 15 mg twice daily is the default in depression trials. Once-daily 28–30 mg is used in several branded-extract mood studies and is pharmacokinetically acceptable.

  • Half-life: Oral crocetin half-life is about 6.1–7.5 hours, with peak levels at 4.0–4.8 hours (Umigai et al., 2011).

  • Genetics: No dose rule for CYP2C9 (a drug-metabolizing enzyme), APOE4 (an Alzheimer-risk gene), or MTHFR (a folate-processing gene). Macular-risk genotypes did not erase the retinal signal.

  • Sex: No routine sex-specific milligram adjustment. PMS protocols use the same 30 mg/day total as mixed-sex depression trials.

  • Age: Older adults in Alzheimer and macular trials used 20–30 mg/day without a separate geriatric schedule. Older-adult protocols often begin at 15 mg/day when drowsiness or use of many other medicines is prominent.

  • Baseline biomarkers: Lower mood or poorer sleep at baseline tracks with a larger questionnaire change. Glucose effects are mainly relevant when fasting glucose or glycated hemoglobin is already high.

  • Pre-existing conditions: Active bipolar illness, pregnancy, and saffron allergy change whether a protocol is used at all; they are not titration details.

Discontinuation & Cycling

  • Duration: Mood, sleep, and retinal protocols are typically weeks to months, not a defined short course. Some users continue indefinitely while the target symptom remains.

  • Withdrawal: No saffron-specific withdrawal syndrome is described. Stopping does not require a taper in published trials.

  • Taper: Optional 1-week step from 30 mg to 15 mg if the extract was used with an antidepressant and both are being changed at once.

  • Cycling: No evidence that scheduled off-weeks preserve efficacy. Loss of effect is more often product quality or a waning placebo run-in than receptor tolerance.

  • After stopping: Mood or sleep scores that rose on extract generally drift toward baseline over weeks; that pattern is inferred from trial washouts, not a formal relapse study.

Sourcing and Quality

  • Plant part: Stigma extract is the clinically studied form. Petal or tepal extracts are different plant-chemical mixtures and should not be assumed equivalent.

  • Standardization: Trial-matched products typically state quantified crocin and safranal (often ≥2% safranal and a stated crocin fraction) and ISO 3632 (the international laboratory spice-grade standard) when the raw material is disclosed.

  • Branded extracts used in trials: affron (Pharmactive), Safr’Inside (Activ’Inside), and Satiereal appear by name in randomized trials. Manufacturer funding is common.

  • Authenticity: ConsumerLab and university tests have found retail products with little or no saffron chemistry. Third-party assays (ConsumerLab, USP, NSF, or ISO-method high-performance liquid chromatography (HPLC)) matter more here than for many cheaper botanicals.

  • Storage: Crocin and safranal degrade with light, heat, and moisture. Opaque, tightly closed containers at room temperature preserve potency.

  • Reputable supply: Life Extension Optimized Saffron and other ConsumerLab-approved lots are examples of tested retail products; passing a current assay is more important than any brand name.

Practical Considerations

  • Time to effect: Mood and sleep questionnaires often move by 1–2 weeks and more clearly by 4–8 weeks. Cognitive and retinal electrical changes were measured at 12–16 weeks or longer.

  • Common pitfalls: Buying untested inexpensive “saffron” capsules; using culinary spice in unmeasured amounts as if it were a 30 mg extract; combining several serotonergic botanicals; expecting a healthy-person “longevity” effect that trials have not measured.

  • Regulatory status: In the United States the extract is sold as a dietary supplement, not as an approved antidepressant or Alzheimer drug. Claims are structure/function, not disease-treatment approvals.

  • Cost and access: A month of 30 mg extract is typically modest, unlike culinary spice by weight. Insurers reimburse generic SSRIs and donepezil or memantine, not saffron extract, a coverage gap that can bias guidelines and research funding.

  • Expectancy: Placebo response in recent low-mood trials is large. A 12-week branded-extract study (Lopresti et al., 2025) still beat placebo on depression scores, but secondary outcomes often did not.

Interaction with Foundational Habits

  • Sleep: Direct and potentiating. Extract can raise subjective sleep quality and duration via serotonergic and circadian-adjacent effects. Evening dosing is the usual pairing; it is not a sedative-hypnotic substitute.

  • Nutrition: Indirect. No specific diet is required. Taking capsules with food may ease nausea. Glucose-lowering in diabetes is an add-on to, not a replacement for, carbohydrate control.

  • Exercise: None established as blunting or boosting hypertrophy. One recreational-athlete trial (Lopresti & Smith, 2022) reported mental more than performance effects. Timing around workouts is optional.

  • Stress management: Potentiating. Mood and anxiety score changes sit on the same stress-hormone and serotonin pathways that breath work and cognitive therapy target. Extract is an add-on, not a stand-alone stress practice.

Monitoring Protocol & Defining Success

Baseline typically includes a numbered scale of the target complaint (mood, sleep, or both), sitting blood pressure, and — if metabolic effects are of interest — a fasting glucose and glycated hemoglobin. A pregnancy test belongs in that baseline whenever pregnancy is possible. The same mood or sleep scale is typically repeated at 2 weeks, 4 weeks, and 8 weeks; blood pressure is typically rechecked at 2–4 weeks if antihypertensive drugs are already in use; and metabolic labs are typically repeated at 3 months only if glucose was a reason for starting. Ongoing review every 3–6 months is enough once a stable dose is in place. Success is a sustained improvement on the same scale used at baseline — for example a several-point drop on a depression or insomnia inventory — without new drowsiness, nausea, or unplanned blood-pressure or glucose dips.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Depression or anxiety scale (PHQ-9 or DASS-21) No saffron-specific target; track change from the person’s own baseline (PHQ-9 <5 is a common remission mark) Documents the primary mood outcome used in trials PHQ-9 is the Patient Health Questionnaire-9; DASS-21 is the Depression Anxiety Stress Scales. Not fasting-dependent.
Sleep scale (PSQI or ISI) No saffron-specific target; track change (PSQI <5 is often called good sleep) Documents sleep response PSQI is the Pittsburgh Sleep Quality Index; ISI is the Insomnia Severity Index. Morning completion is fine.
Sitting blood pressure 110–120 / 70–80 mmHg Detects additive lowering Conventional clinic goal is often <130/80 mmHg. Morning, seated, two readings.
Fasting glucose 70–85 mg/dL Detects glycemic shift in diabetes Conventional reference is typically 70–99 mg/dL. 8–12 hour fast.
Glycated hemoglobin 4.8–5.3% Three-month sugar exposure HbA1c is glycated hemoglobin, the three-month sugar average. Conventional prediabetes cut is 5.7%. Not fasting-dependent. Pair with fasting glucose.
Pregnancy test (urine hCG) Negative before a therapeutic course Avoids uterine-stimulation exposure hCG is human chorionic gonadotropin. Repeat if menses are late.

Qualitative markers:

  • Morning mood and motivation
  • Sleep onset, night waking, and next-day alertness
  • Between-meal snacking urge
  • Sexual function if an SSRI is also used
  • Nausea, dry mouth, or unexpected drowsiness
  • Bruising or bleeding gums if anticoagulants are also used

Emerging Research

  • Larger low-mood trial already completed: A 202-person 12-week affron study (28 mg/day) improved depression scores versus placebo (Cohen’s d 0.39, a standardized effect size in the small-to-moderate range) but not several secondary outcomes, with a large placebo response (Lopresti et al., 2025).

  • Null subclinical-mood trial: A 51-person 6-week extract study did not beat placebo on a composite of depression, anxiety, and fatigue, which weakens extrapolation from clinic depression to “wellness” use (Amadieu et al., 2025).

  • Recruiting sleep trial: NCT07497698 (SAFFRON-SLEEP, University of Granada; n=80, recruiting) tests 30 mg/day for 6 weeks with actigraphy sleep efficiency as the primary endpoint in middle-aged adults.

  • Recruiting metabolic tepal study: NCT07261475 (ZAFRAN; n=20, recruiting) tests a cold water extract of Crocus sativus tepals — not stigma extract — on post-meal glucose in obesity or prediabetes.

  • Independent replication still pending: Most positive Alzheimer and early depression trials remain small and geographically concentrated (Avgerinos et al., 2020). A large, independently funded, multi-country depression trial would move the high-evidence mood claim; a second null wellness trial would narrow the longevity use case.

Conclusion

Saffron extract is a standardized preparation of the dried red threads of Crocus sativus, usually taken at 15 to 30 milligrams a day. For adults already investing in sleep, mood, and long-term brain and eye function, the strongest human signal is a reduction in mild-to-moderate depressive symptoms that, in pooled trials, looks similar to common antidepressant drugs and appears with fewer day-to-day side effects. Sleep quality, anxiety scores, and selected cognitive and retinal measures have supportive but thinner trial data. Metabolic and appetite effects are modest.

The evidence base is a mix of independent academic psychiatry trials and later branded-extract studies paid for by manufacturers. Insurers typically cover the comparison antidepressants and Alzheimer drugs, not the extract, which can tilt guidelines and funding toward those agents. That mix does not erase the mood finding. Sleep and “wellness” claims rest on thinner, more sponsor-dependent data than the clinical-depression findings. At studied capsule doses the extract has been well tolerated. The serious historical harms — poisoning and womb-contracting effects — sit at gram amounts of the spice, not at milligram extract doses, which is why pregnancy remains an avoidance setting rather than a reason to treat food-spice use as dangerous.

Quality is a practical limiter. Authenticated, lab-tested extracts are the form that matches the trials; many inexpensive untested capsules do not. Used that way, saffron extract is a mood-and-sleep intervention with a comparatively gentle side-effect profile, not a proven lifespan drug.

Top - Benefits - Risks - Protocol